Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

INTRODUCTION: The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary function (%FVC < 50%) of patients with idiopathic pulmonary fibrosis (IPF). However, there is no sufficient evidence in real world. OBJECTIVES: Reveal the utility and...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Drug Des Devel Ther
Huvudupphovsmän: Abe, Mitsuhiro, Tsushima, Kenji, Sakayori, Masashi, Suzuki, Kenichi, Ikari, Jun, Terada, Jiro, Tatsumi, Koichiro
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2018
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6186773/
https://ncbi.nlm.nih.gov/pubmed/30349191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S179427
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk